Compare Johnson & Johnson (JNJ) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs VF Corp — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while VF Corp trades at $15 (market cap $5.71B). The key difference: Johnson & Johnson is far larger — about 108.2× VF Corp's market cap, and VF Corp pays the higher dividend (2.48%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and VF Corp for 65 Days on average.
| JNJ | VFC | |
|---|---|---|
Market Cap | $618.09B | $5.71B |
Volume | 6,050,983 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $21.55 |
52-Week Low | $186.00 | $12.62 |
Typical Hold Time | 129 Days | 65 Days |
Enterprise Value | $646.37B | $10.00B |
Dividend Yield | 2.09% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
VFC trades at $14.53, up 1.04% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $11.8B in 2022 to $9.5B in 2025 and negative net income of -$189.72M, though 2026 projects a return to profitability. Analyst consensus is Hold with a $18.33 price target, representing 26% upside. Recent news highlights Vans brand weakness offset by Outdoor segment strength.
The outlook remains cautious with execution risk around the Vans turnaround being the key challenge. The discounted valuation (P/S 0.61) offers potential upside if management can stabilize operations, but persistent revenue declines and recent dividend cut signal ongoing headwinds. Risk-reward appears balanced near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
